Gemini Therapeutics Inc. (GMTX)
$23.93
$2.71
(12.77%)
As on 17-Feb-2023 09:30EDT
Market cap
$58 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
0.7
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$-43 Mln
-
ROE
-0.4 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
0.8
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$--
-
Face value
--
-
Shares outstanding
43,328,300
Years Aggregate
CFO
$--
EBITDA
$--
Net Profit
$--
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Gemini Therapeutics (GMTX)
| 20.3 | -- | 42.9 | 33.7 | -- | -- | -- |
|
BSE Sensex*
| -9.3 | 2.1 | 3.0 | -5.3 | 6.9 | 7.8 | 11.1 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2022
|
2021
|
|---|---|---|
|
Gemini Therapeutics (GMTX)
| -31.6 | -73.5 |
|
S&P Small-Cap 600
| -17.4 | 25.3 |
|
BSE Sensex
| 4.4 | 22.0 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Gemini Therapeutics (GMTX)
|
23.9 | 58.5 | 0.0 | -43.4 | -- | -40.2 | -- | 0.7 |
| 4.9 | 26.5 | 0.1 | -16.7 | -46,093.9 | -71.7 | -- | 0.8 |
Shareholding Pattern
View DetailsAbout Gemini Therapeutics (GMTX)
Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of... the human complement factor H protein to treat dry AMD patients. The company also develops GEM307 for treatment of systemic diseases. Gemini Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts. Read more
-
Interim Pres & CEO and Exec. Chairperson
Dr. Georges Gemayel C.F.A., Ph.D.
-
Interim Pres & CEO and Exec. Chairperson
Dr. Georges Gemayel C.F.A., Ph.D.
-
Headquarters
Cambridge, MA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Gemini Therapeutics (GMTX)
What is the current share price of Gemini Therapeutics Inc (GMTX) Today?
The share price of Gemini Therapeutics Inc (GMTX) is $23.93 (NASDAQ) as of 17-Feb-2023 09:30 EDT. Gemini Therapeutics Inc (GMTX) has given a return of 33.69% in the last 1 years.
What is the current PB & PE ratio of Gemini Therapeutics Inc (GMTX)?
Since, TTM earnings of Gemini Therapeutics Inc (GMTX) is negative, P/E ratio is not available.
The P/B ratio of Gemini Therapeutics Inc (GMTX) is 0.68 times as on 17-Feb-2023, a 86 discount to its peers’ median range of 4.96 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2021
|
--
|
--
|
|
2020
|
--
|
--
|
|
2019
|
--
|
--
|
|
2018
|
--
|
--
|
|
2021
|
--
|
--
|
What is the 52 Week High and Low of Gemini Therapeutics Inc (GMTX)?
The 52-week high and low of Gemini Therapeutics Inc (GMTX) are Rs -- and Rs -- as of 17-Jun-2026.
What is the market cap of Gemini Therapeutics Inc (GMTX)?
Gemini Therapeutics Inc (GMTX) has a market capitalisation of $ 58 Mln as on 17-Feb-2023. As per SEBI classification, it is a Small Cap company.
Should I invest in Gemini Therapeutics Inc (GMTX)?
Before investing in Gemini Therapeutics Inc (GMTX), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.